SENBITEC, established in 2012, is a medical and aesthetic laser manufacturing company specializing in CO₂ and diode laser technologies. The company develops and supplies laser systems applicable to dermatology, gynecology, plastic surgery, and various other clinical fields. Based on its ISO 13485 quality management system, SENBITEC manages the entire process from design to production. With CE certification and U.S. FDA 510(k) clearance for its products, the company continues to strengthen its competitiveness in the global market. SENBITEC focuses on advancing high-output, high-precision laser control technologies, emphasizing safety, clinical effectiveness, and user convenience as its core values.
Currently, SENBITEC exports medical laser devices to approximately 40 countries, including Poland, France, Taiwan, Vietnam, Mexico, and Iran, establishing stable sales networks across Europe, Asia, and the Middle East. In particular, CO₂ laser products are supplied to dermatology clinics in Poland and France, while in Vietnam the company collaborates with A&T Medical to conduct product seminars and technical training, expanding its local market presence. Based on these overseas achievements, the company recorded approximately 60% year-over-year growth in device sales.
At KIMES 2026, SENBITEC will showcase its main product lineup, including the CO₂ laser ‘HESTIA’ and the diode laser models ‘HESTIA MONOLUX’ and ‘HESTIA TRIOLUX.’ The company aims to strengthen global brand recognition, expand engagement with domestic and international buyers and medical professionals, and identify new distribution and cooperation partners. On-site demonstrations and technical consultations will be conducted to directly present the products’ clinical applicability and advanced control technologies.
The flagship CO₂ laser system, HESTIA, integrates both Surgical and Fractional functions into a single device, enabling adaptability across various treatment environments. Built on a 40W high-output platform with precise control and high-speed scanning capability, it is designed to shorten procedure time while minimizing skin damage. Its intuitive user interface (UI) and consistent beam quality enhance procedural accuracy and operational efficiency.
Among the diode laser lineup, HESTIA MONOLUX features up to 1100W high output supported by 10 high-efficiency diode modules and a 15Hz high repetition rate, enabling rapid and continuous treatments. Equipped with a powerful cooling system to reduce discomfort associated with high output, it also offers a large 12mm x 24mm spot size to improve procedural efficiency. HESTIA TRIOLUX simultaneously emits three wavelengths—755nm, 810nm, and 1064nm—allowing energy delivery at multiple skin depths and enabling comprehensive treatment effects.
SENBITEC has identified Europe, including Poland and France, as its core target market, leveraging its CE-certified distribution structure to pursue long-term market establishment. In Asia, Vietnam has been designated as a strategic country, with strengthened collaboration with local partners, while supply expansion continues in Latin America, including Mexico, in response to increasing demand for medical aesthetic procedures. Additionally, based on the FDA 510(k) clearance of HESTIA L200-A, the company is preparing for phased entry into the North American market.
Moving forward, SENBITEC plans to complete its transition to CE MDR to enhance regulatory stability in Europe and expand its global network through participation in major exhibitions across North America and the APAC region. Beyond product sales, the company intends to implement clinical collaborations and educational programs to build a growth structure centered on long-term partnerships.